

Application No. 10/507,000  
Amdt. dated 7 May 2010  
Reply to Office Action of 3 February 2010

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-4. (cancelled)

5. (previously presented) The method of claim 9, wherein the active agent is present in a composition selected from pharmaceutical compositions, foodstuffs, food supplements and beverages.

6. (previously presented) The method of claim 9, wherein the active agent is present with one or more additional active agents.

7. (currently amended) The method of claim 6, wherein the one or more additional active agent is selected from, but not limited, to cholinesterase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors, anti-cholinergics, acetylcholine agonists, serotonin agonists, AMPA receptor agonists, GABA receptor agonists, NMDA receptor agonists,  $\beta$ -adrenoreceptor agonists, digoxin, dobutamine, antiinflammatories, neurotrophic factors, statins, adenosine A2a receptor antagonists, aldose reductase inhibitors, immunomodulators, cannabinoid agonists, interferon  $\beta$ 3 or tricyclic anti-depressants.

8. (cancel)

9. (currently amended) A method for the treatment of amyotrophic lateral sclerosis (ALS) comprising administering to a human or non-human animal an effective amount of an active agent in the dosage range of about 0.1 to about 25 mg/kg bodyweight, wherein the active agent is sarsasapogenin.